Research Group
- Dr. Peta J. O' Connell, Principal Investigator
- Dr. Joaquin Madrenas, Co-Investigator
- Dr. Robert Zhong, Consultant
- Dr. Li Zhang, Consultant
Location
- Robarts Research Institute, London, Canada
Title
- Induction of Transplantation Tolerance by Endogenous CD8alpha+ Dendritic Cells
Dendritic cells (DC)
are rare leukocytes uniquely specialized for immune surveillance and the
induction of primary immune responses. Traditionally regarded as the
instigators of rejection, it is now recognized that either donor or host DC,
particularly those that are immature, can also modulate immune reactivity and
the induction of tolerance to foreign and self antigens. Recent proposals
attribute this dichotomy of DC function in part to the existence of distinct DC
subsets, although it is likely that the state of DC maturation and/or
activation and local environmental factors also play significant roles. DC can
be divided into distinct subpopulations that differ in phenotype, function and microenvironmental location. Although human and mouse DC
subtypes are phenotypically disparate, there is clear
evidence for similar functional specializations. Mouse CD8a+
DC (distinct from classically described myeloid DC) are the principal DC
subtype identified in the thymus and have been implicated in the regulation of
central and peripheral tolerance. Consistent with these reports, our
preliminary observations have demonstrated that CD8a+
DC possess an innate capacity to impair donor-specific reactivity and prolong
organ allograft survival. The immune-regulatory effect is observed using CD8a+
DC isolated directly from donor spleen, without requiring in vitro culture or
sophisticated manipulation such as genetic engineering. We hypothesize that CD8a+
donor DC suppress allo-antigen specific responses and
prolong allograft survival in the absence of exogenous immunosuppression,
either through the induction of regulatory T cells, and/or the deletion of alloreactive T cells. Testing of this hypothesis will place
the investigators in a powerful position to develop a DC-based,
alloantigen-specific strategy for the reliable induction of tolerance.